An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Slides:

Advertisements

Similar presentations

BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.

Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Valsartan Antihypertensive Long-Term Use Evaluation Results

Type 2 diabetes and high blood pressure How explosive is the cocktail?

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Ambulatory blood pressure as a predictor of cardiovascular risk: What’s new?

Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.

Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.

Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.

Antonio Coca, MD, PhD, FRCP, FESC

Dr John Cox Diabetes in Primary Care Conference Cork

a cautionary note from SPRINT

a cautionary note from SPRINT

The SPRINT Research Group

Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus

Copyright © 2011 American Medical Association. All rights reserved.

Hypertension in the Post SPRINT era

Blood Pressure and Age in Controlling Hypertension

LEADER trial: Primary Outcome

Copyright © 2011 American Medical Association. All rights reserved.

Disclosure Consultations and Honoraria Grant Support

Copyright © 2007 American Medical Association. All rights reserved.

United States Preventive Services Task Force: Recommendations for ABPM

Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly by Toshio Ogihara, Takao Saruta, Hiromi Rakugi, Hiroaki Matsuoka,

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Valsartan in Acute Myocardial Infarction Trial Investigators

51st Annual Scientific Session for the LIFE Investigators

Systolic Blood Pressure Intervention Trial (SPRINT)

Progress and Promise in RAAS Blockade

on behalf of the LEADER Trial Steering Committee and Investigators

366 میلیون نفر در جهان مبتلا به دیابت هستند.

Baseline characteristics of patients

The Hypertension in the Very Elderly Trial (HYVET)

Growing Diabetes Pandemic Worldwide

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

(p for noninferiority < 0.001)

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

Potential mechanisms whereby statins may reduce the risk of stroke

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Baseline Characteristics of the Subjects*

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Associations between type of MI and incident HF

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Relationship between updated systolic blood pressure (SBP), right, and updated HbA1c, left, and the incidence of microvascular complications (closed symbols)

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

HR for myocardial infarction.

Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative.

Presentation transcript:

CV events in T2DM patients according to standard or intensive BP treatment and glycemic control An ACCORD BP sub-analysis HR: 1.06; 95%CI: 0.83-1.36; P=0.61 HR: 0.71; 95%CI: 0.56-0.90; P=0.005 CV events included CV death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for congestive heart failure; CV: cardiovascular; T2DM: type 2 diabetes; SBP: systolic blood pressure; ACCORD BP: Action to Control Cardiovascular Risk in Diabetes Blood Pressure; HbA1c: glycated hemoglobin; Tsujimoto et al. Hypertension 2018